These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. LCP-Tacrolimus Extended-Release (Envarsus XR) Use in Adolescent and Young Adult Solid Organ Transplant Recipients. Bae EK, Chandran MM, Everitt MD, Benz E, Bock M. Clin Transplant; 2024 Aug; 38(8):e15417. PubMed ID: 39087462 [Abstract] [Full Text] [Related]
9. MeltDose Technology vs Once-Daily Prolonged Release Tacrolimus in De Novo Liver Transplant Recipients. Baccarani U, Velkoski J, Pravisani R, Adani GL, Lorenzin D, Cherchi V, Falzone B, Baraldo M, Risaliti A. Transplant Proc; 2019 Nov 16; 51(9):2971-2973. PubMed ID: 31607620 [Abstract] [Full Text] [Related]
10. Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies. Vadcharavivad S, Saengram W, Phupradit A, Poolsup N, Chancharoenthana W. Drugs; 2019 Dec 16; 79(18):1947-1962. PubMed ID: 31713065 [Abstract] [Full Text] [Related]
12. Clinical Experience with Extended-Release Tacrolimus in Older Adult Kidney Transplant Recipients: A Retrospective Cohort Study. January SE, Hagopian JC, Nesselhauf NM, Progar K, Horwedel TA, Santos RD. Drugs Aging; 2021 May 16; 38(5):397-406. PubMed ID: 33755934 [Abstract] [Full Text] [Related]
13. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study. Hiramitsu T, Tomosugi T, Futamura K, Okada M, Nishihira M, Goto N, Ichimori T, Narumi S, Kobayashi T, Uchida K, Watarai Y. Int Immunopharmacol; 2021 Feb 16; 91():107038. PubMed ID: 33388731 [Abstract] [Full Text] [Related]
16. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations. Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Yamamoto R, Habuchi T, Satoh S, Miura M. Clin Exp Nephrol; 2017 Oct 16; 21(5):787-796. PubMed ID: 28271256 [Abstract] [Full Text] [Related]
18. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group. Kidney Int; 2019 Jul 16; 96(1):231-244. PubMed ID: 31027892 [Abstract] [Full Text] [Related]
19. Extended-release tacrolimus dosing and outcomes in pediatric and young adult transplant recipients - A single-center experience. Huang X, Hapgood K, Allan K, Pruette C, Goswami E. Pediatr Transplant; 2024 Feb 16; 28(1):e14611. PubMed ID: 37735900 [Abstract] [Full Text] [Related]